Guidant Stresses Rapid Contak Physician Training To Make Up For Lost Time
This article was originally published in The Gray Sheet
Executive Summary
Guidant has set a goal of training at least 800 physicians on use of its Contak CD by the end of June. The implantable cardioverter defibrillator was approved May 2 for resynchronization therapy to treat heart failure
You may also be interested in...
Heart Failure Device Trials Lack Risk “Trade-Off” Data – CDRH’s Zuckerman
Heart failure device trials should be powered to measure differences in mortality compared with the control, even if mortality reduction is not the therapy's primary goal, according to CDRH Cardiovascular Devices Branch Chief Bram Zuckerman, MD
Heart Failure Device Trials Lack Risk “Trade-Off” Data – CDRH’s Zuckerman
Heart failure device trials should be powered to measure differences in mortality compared with the control, even if mortality reduction is not the therapy's primary goal, according to CDRH Cardiovascular Devices Branch Chief Bram Zuckerman, MD
CRT Should Slow Heart Failure Progression, Not Merely Lift Symptoms – Panel
Peak VO2 level is an impractical endpoint to use in clinical trials of cardiac resynchronization therapy (CRT) devices, panelists agreed at a recent Heart Failure Society of America event in Washington, D.C